Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 247 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Male and Female Subjects Clear all

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Atherosclerosis
Interventions: Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Renal Impairment, Disease Severity
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Alzheimer's Disease
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy Volunteers
Interventions: AEF0117 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Drug Interactions
Interventions: Telotristat etiprate, Midazolam; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Healthy Volunteers
Interventions: Rilzabrutinib; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Kidney Failure, Chronic
Interventions: ticagrelor; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Healthy
Interventions: Genz-682452, Placebo; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Renal Insufficiency, Healthy
Interventions: Canagliflozin (JNJ-28431754); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Healthy Male and Female Subjects
Interventions: Running, Cycling, Rugby, control group; Other
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boone, North Carolina

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions: CF-301, Placebo; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Lenexa, Kansas • Omaha, Nebraska

Conditions: Healthy
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Overactive Bladder
Interventions: Solabegron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy, Renal Insufficiency
Interventions: MGTA-145; Biological
Lead sponsor: Ensoma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Acinetobacter Baumannii Infection
Interventions: ETX2514SUL; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota

Conditions: Lactose Intolerance
Interventions: RP-G28; Drug
Lead sponsor: Ritter Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Renal Insufficiency
Interventions: QAW039, QAW39A, QAW39A2107; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Ulcerative Colitis
Interventions: Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Renal Disease, End Stage
Interventions: Amisulpride IV, Amisulpride Oral Tablet; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami Lakes, Florida

Search by objective public record fields.

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment